Jazz Pharmaceuticals plc
http://jazzpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jazz Pharmaceuticals plc
Erytech’s Solid Tumor Hopes Falter As Eryaspase Fails In Phase III Pancreatic Cancer Trial
Erytech’s eryaspase has failed in its Phase III TRYbeCA-1 trial for second-line pancreatic cancer despite analyst excitement for the solid tumor indication. Its attentions now turn, once again, to its acute lymphoblastic leukemia indication.
Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.
Apnimed Moves Closer To Phase III With Sleep Apnea Drug
Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.
Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.
Company Information
- Industry
- Biotechnology
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- EUSA Pharma Inc. (Cytogen Corporation
- OPi SA)
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.